Advertisement
Canada markets open in 5 hours 3 minutes
  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • CAD/USD

    0.7330
    +0.0007 (+0.09%)
     
  • CRUDE OIL

    83.87
    +0.30 (+0.36%)
     
  • Bitcoin CAD

    87,808.88
    +508.70 (+0.58%)
     
  • CMC Crypto 200

    1,389.52
    -7.01 (-0.50%)
     
  • GOLD FUTURES

    2,359.20
    +16.70 (+0.71%)
     
  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     
  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     
  • NASDAQ futures

    17,756.00
    +188.50 (+1.07%)
     
  • VOLATILITY

    15.54
    +0.17 (+1.11%)
     
  • FTSE

    8,118.64
    +39.78 (+0.49%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • CAD/EUR

    0.6820
    -0.0001 (-0.01%)
     

Teva Announces Launch of Generic Version of Uceris in US

Teva Announces Launch of Generic Version of Uceris in US

On July 9, Teva announced the launch of its generic Uceris (budesonide) extended-release tablets (nine milligrams) in the United States. In November 2017, Teva prevailed in its litigation challenging Valeant Pharmaceuticals’ (VRX) Uceris patent, which was acquired through the acquisition of Salix in 2015. Teva was the first applicant to file an ANDA (abbreviated new drug application) for generic Uceris.